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Abstract
Type 1 diabetes, as an autoimmune disease, presents several islet cell-
specific autoantibodies such as islet cell antibody (ICA), anti-insulin,
anti-glutamic acid decarboxylase (GAD) and the antibody (Ab) against
tyrosine phosphatase (PTP)-like protein known as ICA-512 (IA-2). In
order to determine the frequency of the anti-GAD and anti-IA-2
autoantibodies in Brazilian type 1 diabetes patients we studied 35
diabetes mellitus (DM) type 1 patients with recent-onset disease (£12
months) and 37 type 1 diabetes patients with long-duration diabetes
(>12 months) who were compared to 12 children with normal fasting
glucose. Anti-GAD65 and anti-IA-2 autoantibodies were detected with
commercial immunoprecipitation assays. The frequency of positive
results in recent-onset DM type 1 patients was 80.0% for GADAb,
62.9% for IA-2Ab and 82.9% for GADAb and/or IA-2Ab. The long-
duration type 1 diabetes subjects presented frequencies of 54.1% for
GADAb and IA-2Ab, and 67.5% for GAD and/or IA-2 antibodies.
The control group showed no positive cases. Anti-GAD and IA-2
assays showed a high frequency of positivity in these Brazilian type 1
diabetes patients, who presented the same prevalence as a Caucasian
population.
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Type 1 diabetes is a chronic autoimmune
disease caused by the destruction of insulin-
secreting islet cells of the pancreas (1,2) by
several islet cell-specific autoantibodies.
These autoantibodies are valuable markers
to predict type 1 diabetes and can be detected
many months or years before the onset of
diabetes (3).
Many autoantibodies against ß-cells have
been identified. The most important ones
are: islet cell antibody (ICA) (1), anti-insulin
(3), anti-glutamic acid decarboxylase (GAD)
(4) and the antibody (Ab) against the ty-
rosine phosphatase (PTP)-like protein known
as ICA-512 (IA-2) (5,6). Antibodies against
GAD and IA-2 can be detected in type 1
diabetes patients using radioimmunoassays.
These autoantibodies have been useful in
differentiating late-onset type 1 from type 2
diabetes occurring in young adulthood (7).
In addition, they have been used to confirm
the autoimmune process in gestational dia-
betes (8) and to separate type 1 diabetes from
other types of non-autoimmune diabetes like
maturity-onset diabetes of the young (9) or
diabetes related to mitochondrial DNA mu-
tation (10). Knowing the frequency of these
autoantibodies in a population is an impor-
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tant step for a better understanding and diag-
nosis of type 1 diabetes.
This study was conducted using com-
mercial assays to determine the frequency of
anti-GAD and anti-IA-2 autoantibodies in
serum of young Brazilian type 1 diabetes
patients with recent-onset and long-duration
diabetes.
We studied 35 type 1 diabetes patients
(16 females, 13.2 – 5.7 years) who had been
diagnosed with diabetes within one year prior
to the study. These subjects were called re-
cent-onset diabetes patients. Thirty-seven
type 1 diabetes patients (19 females, 13.9 –
3.3 years) who had had diabetes for more
than one year were also studied and were
called long-duration diabetes patients. These
groups were compared to 12 children (11.8 –
4.4 years) with normal fasting glucose (<100
mg/dl) and no family history of type 1 diabe-
tes (Table 1). The type 1 diabetes patients
were selected while attending a diabetes va-
cation camp and all patients mothers gave
informed consent to collect blood samples to
perform this study. Diabetes was diagnosed
according to World Health Organization cri-
teria (11).
Anti-GAD65 and anti-IA-2 autoantibod-
ies were detected with commercial immuno-
precipitation assays using 125I-labeled hu-
man recombinant GAD65 and IA-2, respec-
tively (RSR Ltda., Cardiff, UK). The lower
detection limit was 0.1 U/ml for both assays.
The reference values used, based on our
controls, for anti-GAD65 and anti-IA-2 were
<1.0 and £0.5 U/ml, respectively. These cut-
off levels for positivity were established us-
ing the 99th percentile of the control groups.
The test serum samples were first incubated
with 125I-labeled human recombinant pro-
tein (GAD65 and IA-2), followed by the ad-
dition of solid phase protein A to precipitate
the labeled protein and antibody complex.
After centrifugation, 125I was counted in the
precipitates. The amount of radioactivity in
the precipitates was proportional to the con-
centration of IA-2 antibody in the test sample.
The intra-assay and the inter-assay coeffi-
cients of variation (CV) for anti-GAD65 were
3.1 and 3.5%, respectively, for normal refer-
ence values. The intra-assay CV for IA-2
was 4.3% and the inter-assay CV was 3.4%
for normal reference values.
Data are reported as mean – SEM, unless
otherwise stated. The Mann-Whitney U-test
was used when comparing two groups. Sta-
tistical analyses were performed using a
Fishers exact probability test. The correla-
tion between two variables was determined
using Spearmans test. Data were analyzed
with the Statistical Package for Social Sci-
ence for Windows, version 7.0 (SPSS Inc.,
Chicago, IL, USA). A P value of less than
0.05 was considered statistically significant.
Among the 35 recent-onset type 1 diabe-
tes patients, 28 (80.0%) were positive for
GADAb, 22 (62.9%) were positive for IA-
2Ab, and 29 (82.9%) were positive for
GADAb and/or IA-2Ab. Among the 37 long-
duration type 1 diabetes subjects, 20 (54.1%)
were positive for GADAb and IA-2Ab, and
25 (67.5%) were positive for GAD and/or
IA-2 antibodies (Table 2). All individuals in
Table 1 - Clinical characteristics of type 1 diabetes patients and control subjects.
F/M, Female/male; ns, nonsignificant (Mann-Whitney U-test).
Type 1 diabetes Control group P
Recent-onset Long-duration
N (F/M) 35 (16/19) 37 (19/18) 12 (3/9)
Age (years) 13.2 ± 5.7 13.9 ± 3.3 11.8 ± 4.4 ns
Duration of diabetes (months) 6.5 ± 4.0 50.7 ± 30.0 - <0.005
Dose of insulin (U/day) 27.6 ± 17.1 44.7 ± 14.4 - <0.005
Table 2 - Prevalence of anti-glutamic acid decarboxylase (GAD) and ICA-512 (IA-2)
antibodies in type 1 diabetes patients with recent-onset and long-duration diabetes
(Fisher’s exact test).
GAD IA-2 GAD and/or IA-2
Recent-onset diabetes 80.0% (28/35) 62.9% (22/35) 82.9% (29/35)
Long-duration diabetes 54.1% (20/37) 54.1% (20/37) 67.5% (25/37)
Control group 0.0% (0/12) 0.0% (0/12) 0.0% (0/12)
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the control group had results within the ref-
erence values. Duration of type 1 diabetes
showed a significant negative correlation
with autoantibody levels (GADAb r = -0.23,
P<0.05; IA-2Ab r = -0.25, P<0.04).
In the recent-onset diabetic population,
GAD frequency was higher than IA-2 fre-
quency and their combination did not in-
crease the prevalence of positive assays.
However, in long-duration type 1 diabetes
patients, combining these antibodies im-
proved the probability of detection of an
autoimmune reaction. The Brazilian popula-
tion studied here had the same GADAb preva-
lence as that reported in Caucasian patients
(65-84%) and Asian type 1 diabetes patients
(5-83.3%) (12-14).
IA-2 autoantibody is present in approxi-
mately 60% of recent-onset type 1 diabetes
patients (15,16), which is consistent with
our findings. Also, testing for both antibod-
ies increases positive results in type 1 diabe-
tes patients, even in long-duration ones.
Some studies have also shown that the
combined analysis of GADAb and IA-2Ab
is more effective in detecting type 1 diabetes
than the histochemical ICA test, which is an
important advantage because the ICA test is
technically difficult to perform, requires hu-
man pancreatic tissue and has low reproduc-
ibility (17,18). Anti-GAD and IA-2 assays
showed a high frequency of positivity in
these Brazilian type 1 diabetes patients and
these patients presented the same prevalence
as a Caucasian population reported by others
(12).
Acknowledgments
We are grateful to the doctors, residents,
nurses and staff of the Nosso Recanto
Diabetes Campus for their help with proto-
cols.
References
1. Eisenbarth GS (1986). Type I diabetes
mellitus: a chronic autoimmune disease.
New England Journal of Medicine, 314:
1360-1368.
2. Leslie RDG & Gale EAM (1995). Etiology
of insulin dependent diabetes. In: Leslie
RDG & Robbins DC (Editors), Diabetes;
Clinical Science in Practice. Cambridge
University Press, Cambridge, 134-156.
3. Verge CF, Gianani R, Kawasaki E, Yu L,
Pietropaolo M, Jackson RA, Chase HP &
Eisenbarth GS (1996). Prediction of type I
diabetes in first degree relatives using a
combination of insulin, GAD and ICA-512/
IA-2 antibodies. Diabetes, 45: 926-933.
4. Baekkeskov S, Aanstoot HJ, Christgau S,
Reetz A, Solimena M, Cascalho M, Folli F,
Richter-Olesen H & DeCamilli P (1990).
Identification of the 64K autoantigen in
insulin dependent diabetes as the GABA-
synthesizing enzyme glutamic acid decar-
boxylase. Nature, 347: 151-156.
5. Rabin DU, Pleasic SM, Shapiro JA, Yoo-
Warren H, Oles J, Hicks JM, Goldstein DE
& Era PMM (1994). Islet cell antigen 512
is a diabetes-specific islet autoantigen re-
lated to protein tyrosine phosphatases.
Journal of Immunology, 152: 3183-3188.
6. Lan MA, Lu J, Goto Y & Notkins AL (1994).
Molecular cloning and identification of a
receptor-type protein tyrosine phospha-
tase, IA-2, form human insulinoma. DNA
and Cell Biology, 13: 505-514.
7. Tuomi T, Groop LC, Zimmet PZ, Rowley
MJ, Knowles W & Mackay IR (1993). Au-
toantibodies to glutamic acid decarboxyl-
ase reveal latent autoimmune diabetes
mellitus in adults with a non-insulin-de-
pendent onset of diabetes. Diabetes, 42:
359-362.
8. Füchtenbusch M, Ferber K, Standl E &
Ziegler AG (1997). Prediction of type 1
diabetes postpartum in patients with ges-
tational diabetes mellitus by combined is-
let cell autoantibody screening. Diabetes,
46: 1459-1467.
9. Dussoix P, Vaxillaire M, Iynedjian PB,
Tiercy JM, Ruiz J, Spinas GA, Berger W,
Zahnd G, Froguel P & Philippe J (1997).
Diagnostic heterogeneity of diabetes in
lean young adults - classification based on
immunological and genetic parameters.
Diabetes, 46: 622-631.
10. Reardon W, Ross RJ, Sweeney MG,
Luxon LM, Pembrey ME, Harding AE &
Trembath RC (1992). Diabetes mellitus
associated with a pathogenic point muta-
tion in mitochondrial DNA. Lancet, 340:
1376-1379.
11. World Health Organization Diabetes Mel-
litus (1985). Report of a WHO Study
Group. Technical Report Series, No. 727,
WHO, Geneva.
12. Schmidli RS, Colman PG & Bonifacio E
(1995). Disease sensitivity and specificity
of 52 assays for glutamic acid decarboxyl-
ase antibodies: The second international
GADAb Workshop. Diabetes, 44: 636-
640.
13. Akamine H, Komiya I, Shimabukuro T,
Asawa T, Tanaka H, Yagi N, Taira T, Nagata
K, Arakaki K, Wakugami T, Takasu N,
Powell MJ, Furmaniak J & Smith BR
(1997). High prevalence of GAD65 (and
IA-2) antibodies in Japanese IDDM pa-
tients by a new immunoprecipitation as-
say based on recombinant human GAD65.
Diabetic Medicine, 14: 778-784.
14. Zimmet PZ, Rowley MJ, Mackay IR,
Knowles WJ, Chen QY, Chapman LH &
Serjeantson SW (1993). The ethnic distri-
1198
Braz J Med Biol Res 32(10) 1999
V.C. Pardini et al.
bution of antibodies to glutamic acid de-
carboxylase: presence and levels in insu-
lin-dependent diabetes mellitus in Euro-
pean and Asian subjects. Journal of Dia-
betes Complication, 7: 1-7.
15. Gorus FK, Goubert P, Semakula C,
Vandewalle CL, De Schepper J, Scheen
A, Christie MR & Pipeleers DG (1997). IA-
2-autoantibodies complement GAD-65-
autoantibodies in new-onset IDDM pa-
tients and help predict impeding diabetes
in their siblings. Diabetologia, 40: 95-99.
16. Vandewalle CL, Falorni A, Lernmark A,
Goubert P, Dorchy H, Coucke W,
Semakula C, Auwera BVD, Kaufman L,
Schuit FC, Pipeleers DG & Gorus FK
(1997). Association of GAD-65 and IA-2
autoantibodies with genetic risk markers
in new-onset IDDM patients and their sib-
lings. Diabetes Care, 20: 1547-1552.
17. Ladenburger UW, Hartmann R, Hartmann
U, Berting K, Böhn BO & Richter W
(1997). Combined analysis and single-step
detection of GAD 65 and IA-2 autoanti-
bodies in IDDM can replace the his-
tochemical islet cell antibody test. Diabe-
tes, 46: 565-571.
18. Borg H, Fernlund P & Sundkvist G (1997).
Protein tyrosine phosphatase-like protein
IA-2-antibodies plus glutamic acid decar-
boxylase 65 antibodies (GADA) indicate
autoimmunity as frequently as islet cell
antibodies assay in children with recently
diagnosed diabetes mellitus. Clinical
Chemistry, 43: 2358-2363.
